Alterity Therapeutics Unveils New MRI-Based Diagnostic Tool to Track Multiple System Atrophy Progression in Clinical Study
Reuters
Jul 24, 2025
<a href="https://laohu8.com/S/ATH.AU">Alterity Therapeutics</a> Unveils New MRI-Based Diagnostic Tool to Track Multiple System Atrophy Progression in Clinical Study
Alterity Therapeutics Ltd. has announced the publication of a novel MRI endpoint from the bioMUSE Natural History Study in the peer-reviewed journal Annals of Clinical and Translational Neurology. The study introduces the MSA Atrophy Index (MSA-AI), a new neuroimaging measure developed to diagnose and track disease progression in Multiple System Atrophy $(MSA)$. Utilizing advanced MRI technology, the research demonstrated that statistically significant reductions in brain volume over 12 months correlated with clinical worsening of MSA. The study captured a broad spectrum of clinical severity and atrophy patterns, effectively distinguishing MSA from related synucleinopathies. The results of this study have been presented and are available in the publication entitled "The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy."
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.